Sherman Darren 4

What Happened Darren Sherman, President and Chief Operating Officer (and director) of Orchestra BioMed Holdings, was granted 397,000 restricted stock units (RSUs) on February 12, 2026. The award was reported as an acquisition/award (code A) at $0.00 per share (no cash payment). These RSUs represent contingent rights to receive common stock in the future subject to vesting.

Key Details

• Transaction date: 2026-02-12; Report filed: 2026-02-13 (timely).
• Grant: 397,000 RSUs; reported price per share: $0.00; immediate cash value reported: $0.
• Shares owned after transaction: not specified in the filing.
• Footnote: Each RSU equals a contingent right to one share. Vesting schedule: 25% vests 18 months after the issue date (Feb 12, 2026), then 25% at 24 months, 25% at 30 months, and 25% at 36 months, subject to continuous service.
• Remarks: Sherman is President and Chief Operating Officer.

Context RSUs are compensation awards that convert into shares only upon vesting; they do not represent immediate transferable stock or a cash outlay by the insider. Such grants are routine forms of executive compensation and do not by themselves indicate an insider buying or selling stock in the open market.